Pharmaceutical company
Issues pertaining to chronic kidney disease, generally; and issues specifically relating to end-stage renal disease (ESRD) drugs, innovation, and reimbursement (including Medicare coverage and reimbursement issues). Issues pertaining to chronic kidney disease, generally; and issues specifically relating to end-stage renal disease (ESRD) drugs, innovation, and reimbursement (including Medicare coverage and reimbursement issues). Issues pertaining to chronic kidney disease, generally; and issues specifically relating to end-stage renal disease (ESRD) drugs, innovation, and reimbursement (including Medicare coverage and reimbursement issues).
BUD - Budget/Appropriations HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce